Efficacy of Oral Tofacitinib in the Treatment of Lichen Planopilaris
TLDR Oral tofacitinib significantly improves lichen planopilaris symptoms without adverse effects.
The study investigated the efficacy of oral tofacitinib in treating lichen planopilaris (LPP), a type of lymphocytic scarring alopecia. Eight patients were treated, showing significant improvement in the LPP activity index (LPPAI) by 30-94% (p=0.0014). Some patients required increased dosage for a measurable response. LPP symptoms flared upon withdrawal of tofacitinib but were controlled again upon re-initiation. No adverse effects or significant changes in laboratory values were reported. The findings suggested that JAK inhibitors like tofacitinib could be a promising treatment for LPP, warranting further randomized placebo-controlled trials.
